Study on Effects of Hemp-Derived Cannabinoids on Menopause and Perimenopause Symptoms in Women Aged 40 to 60

What this Trial Is About

Researchers are studying the effects of hemp-derived minor cannabinoids on symptoms experienced during menopause and perimenopause. This randomized, double-blind, placebo-controlled trial aims to understand how these cannabinoids may influence psychological and physical symptoms in women aged 40 to 60. The study spans three months and includes careful monitoring of emotional, cognitive, and physical health factors associated with menopause. Participants will be randomly assigned to receive either an active hemp-derived cannabinoid product or a placebo, taken three times daily after meals. The study includes a baseline period of four weeks with twice-daily symptom and sleep surveys, weekly cognitive testing via smartphone, and monthly Zoom sessions for detailed cognitive assessments and symptom surveys. Following baseline, two phases of four weeks each will continue with the assigned product, maintaining the same schedule of surveys, cognitive tests, and Zoom assessments. During the study, participants will complete frequent ecological momentary assessments EMA twice daily to report symptoms and side effects, along with weekly cognitive tests on memory, attention, and reaction time. Monthly Zoom sessions will include comprehensive cognitive tests and surveys assessing depression, anxiety, stress, sleep, and memory. Researchers will closely monitor mood, physical symptoms, side effects, and cognitive function throughout the three-month study to evaluate the impact of the cannabinoids on menopause symptoms.

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms